Authors


Lawrence Steinman, MD

Latest:

Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis - Recent Updates

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.


Teri Schreiner, MD

Latest:

Balancing COVID-19 Infection Risk and Disease Control in Pediatric Onset MS: Teri Schreiner, MD

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]


Caroline Just, MD, FRCPC, CSC-EEG

Latest:

Rare Diseases Are More Common Than Their Name May Imply

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.


Adel M. Malek, MD, PhD

Latest:

A New Approach to Communicating Hydrocephalus: An Overdue Opportunity

A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.


Ruth Ann Marrie, MD, PhD, FRCPC

Latest:

Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPC

The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]


David T. Jones, MD

Latest:

Implementing New Diagnostic Criteria of Limbic-Predominant Amnestic Neurodegenerative Syndrome in Clinical Practice: Nick Corriveau-Lecavalier, PhD & David T. Jones, MD

A duo of experts from Mayo Clinic discussed how recent developments in clinical criteria for diagnosing limbic-predominant amnestic neurodegenerative syndrome allow for more accurate differentiation from Alzheimer disease. [WATCH TIME: 9 minutes]


Michael Hotchkin

Latest:

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]


Benjamin Claytor, MD

Latest:

Understanding the Utility of Specific Antibody Testing in Peripheral Neuropathies: Benjamin Claytor, MD

The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]


Jemima Akinsanya, DO

Latest:

Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhD

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.


Carlos A. Pardo-Villamizar, MD

Latest:

Patient-Centric Theme of SRNA’s 2022 Rare Neuroimmune Disorders Symposium: Carlos A. Pardo-Villamizar, MD

The professor of neurology at Johns Hopkins Medicine provided an in-depth look at the 2022 RNDS and the unique design it offers patients with rare neuroimmune disorders. [WATCH TIME: 3 minutes]


Jai Perumal, MD

Latest:

Benefits of Telemedicine and Access to Treatments for Multiple Sclerosis: Jai Perumal, MD

The associate professor of clinical neurology at Weill Cornell Medicine discussed the progress made in multiple sclerosis in terms of expanding access to therapies and the challenges that persist for progressive forms of the disease in the field. [WATCH TIME: 10 minutes]


Nicholas E. Johnson, MD, MSci

Latest:

Successes and Challenges in the New Era of Genetic Medicine: Nicholas E. Johnson, MD, MSci

The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]


Mustafa Saad Siddiqui, MD

Latest:

COVID-19 Shutdowns and the Disruption to Deep Brain Stimulation Treatment

While shutdowns disrupted care for all patients with Parkinson disease, hospitals were forced to postpone elective procedures such as the initial DBS device implantation and implantable pulse generator replacements.


Michael Kaplitt, MD, PhD

Latest:

The Promising Future of Gene Therapy in Treating Neurological Diseases: Michael Kaplitt, MD, PhD

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]


Amanda Hare, DNP

Latest:

Improving Access to Care in Parkinson Disease: Expanding Objective Diagnostics and Telemedicine

Standardizing protocols and incorporating objective diagnostics and telemedicine can enhance care for patients with PD and alleviate the burden on healthcare systems.


Louis Ferrari, RPh, MBA

Latest:

Balancing New Medications and Reducing Adverse Effects in Epilepsy Treatment: Louis Ferrari, RPh, MBA

The vice president of medical affairs at SK Life Science talked about findings from a new post-hoc analysis which highlighted the importance of strategically reducing concomitant medications to minimize adverse events of epilepsy treatment. [WATCH TIME: 5 minutes]


Lori Lonczak, MBA, RPh

Latest:

Digital Health Tool Offers Innovative Quantitative Fall Assessment Solution for Older Adults

Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.


Marian LaMonte, MD, MSN, FAAN

Latest:

Improving Stroke Discharge Outcomes: Marian LaMonte, MD, MSN, FAAN

The chief of neurology at Ascension Saint Agnes discussed the interventions her team implemented to improve patient-specific stroke discharge instructions.


Jessica Yi, MD

Latest:

A Practical Approach to Chronic Immunosuppression in Myasthenia Gravis

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.


Laurits Taul Madsen, PhD-C

Latest:

Using Neuromuscular Function as a Risk Factor for Falls in Multiple Sclerosis: Laurits Taul Madsen, PhD-C

The PhD student at Aarhus University provided insight on his study presented at 2022 ECTRIMS Congress on an innovative way using neuromuscular measures to discriminate those with MS at high risk for falls. [WATCH TIME: 2 minutes]


Andreas Charidimou, MD, PhD

Latest:

Considerations to Better Diagnose Nonhemorrhagic Cerebral Amyloid Angiopathy: Andreas Charidimou, MD, PhD

The neurologist and assistant professor at Boston University Medical Center provided forward thoughts on improving the diagnosis of milder, asymptomatic cases of cerebral amyloid angiopathy. [WATCH TIME: 4 minutes]


Josh Cohen, BSc

Latest:

Reactions to FDA Advisory Panel Decision on AMX0035: Justin Klee; Josh Cohen, BSc

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]


Gabriel Pardo, MD, FAAN

Latest:

Recommendations for RRMS Management

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.


Sara Hantgan, BSI-C

Latest:

Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care

Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.


Kevin Chang, PharmD

Latest:

Unwinding Histone Deacetylase Inhibitors: Givinostat in Duchenne Muscular Dystrophy

Amifampridine enhances neuromuscular transmission and relieves muscle weakness, showing promise for Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.


Anthony Feinstein, MPhil, PhD, FRCP

Latest:

The Challenge of Treating Fatigue in Multiple Sclerosis: Anthony Feinstein, MPhil, PhD, FRCP

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]


Danielle Becker, MD, MS, FAES

Latest:

Emphasizing Patient Conversations and Treatment Opportunities for Seizure Management: Danielle Becker, MD, MS, FAES

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center talked about the impact of ongoing seizures in patients with drug-resistant epilepsy and the importance of education for emerging opportunities in epilepsy care. [WATCH TIME: 3 minutes]


Jenn Orthmann-Murphy, MD, PhD

Latest:

The Complexity of Immune Cell Interactions and Potential Treatments for MS: Jenn Orthmann-Murphy, MD, PhD

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]


Susan W. Broner, MD

Latest:

Understanding Headache Essentials for General Neurologists: Susan W. Broner, MD

The medical director of the Weill Cornell Medicine Headache Program discussed key essential knowledge on the diagnosis, treatment, and pathophysiology of different headache types. [WATCH TIME: 6 minutes]


Joanna Hellmuth, MD, MS

Latest:

Future Research on the Pathogenesis of COVID-19, Cognitive Changes: Joanna Hellmuth, MD, MS

The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them. [WATCH TIME: 4 minutes]

© 2024 MJH Life Sciences

All rights reserved.